← Eichor
Study identifier: NCT06527495 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma

Condition: HCC · Hepatocellular Carcinoma  ·  Sponsor: Assiut University

PhasePhase 1/Phase 2
Planned participants150
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic polymorphisms.

This description comes directly from the study's public registry record.

Talk to the study team

Mahmoud Nazih  ·  00201093859868  ·  Mahmoud.Nazih5698@pharm.aun.edu.eg

Always discuss trial participation with your own doctor first.

Locations (1)

NLIShibīn al Kawm, Menoufia, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06527495